OTCMKTS:SPHDF Santhera Pharmaceuticals (SPHDF) News Today $10.29 0.00 (0.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$10.29▼$10.2950-Day Range$0.68▼$10.2952-Week Range$0.68▼$1.20VolumeN/AAverage Volume3,788 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A HeadlinesProfileChartCompetitorsHeadlinesShort InterestProfileChartCompetitorsHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSanthera Pharmaceuticals reports 1H resultsseekingalpha.com - September 8 at 5:50 AMSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The Cornerfinance.yahoo.com - September 8 at 5:50 AMSanthera Announces Half-Year 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - September 7 at 2:52 AMSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi Groupbenzinga.com - July 31 at 10:30 AMH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)markets.businessinsider.com - July 31 at 10:30 AMSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Splitfinanznachrichten.de - June 29 at 1:27 AMSanthera Publishes Timeline of the Reverse Share Splitfinance.yahoo.com - June 29 at 1:27 AMSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meetingfinanznachrichten.de - June 27 at 12:51 PMShareholders Approve all Board Proposals at Today’s Annual General Meetingfinance.yahoo.com - June 27 at 12:51 PMCatalyst (CPRX) to Gain DMD Drug Licensing Rights From Santheramsn.com - June 21 at 9:55 AMCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticalsfinance.yahoo.com - June 20 at 7:03 AMSanthera Grants North America License For Vamorolone To Catalyst Pharmamarkets.businessinsider.com - June 20 at 1:46 AMSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royaltiesfinance.yahoo.com - June 20 at 1:46 AMSanthera Publishes Agenda for its Annual General Meetingfinance.yahoo.com - June 6 at 4:19 AMSanthera Pharmaceuticals GAAP EPS of -CHF1.17seekingalpha.com - June 2 at 10:21 AMSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022finanznachrichten.de - June 1 at 10:18 AMSanthera Publishes Annual Report 2022finance.yahoo.com - May 31 at 7:41 PMSanthera -- A Duchenne Drug With Positive Study Results That Few Know Aboutthestreet.com - May 24 at 8:06 AMSanthera Drug Wins European Approval for Rare Blindness Diseasethestreet.com - May 13 at 12:18 AMSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Updatefinance.yahoo.com - April 27 at 9:35 AMSanthera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completedfinanznachrichten.de - April 25 at 9:42 AMVamorolone NDA mid-cycle review meeting by FDA completedfinance.yahoo.com - April 25 at 9:42 AMSanthera Pharmaceuticals Holding AG (VTX:SANN) Is Expected To Breakeven In The Near Futurefinance.yahoo.com - April 1 at 2:39 AMSanthera Pharmaceuticals Holding AGbarrons.com - March 30 at 2:11 PMSanthera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - March 2 at 1:49 AMSanthera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolonefinance.yahoo.com - February 8 at 1:27 AMSanthera Pharmaceuticals Holding AG: Santhera enters into CHF 5 million share exchange agreementfinanznachrichten.de - January 10 at 8:39 AMSanthera enters into CHF 5 million share exchange agreementfinance.yahoo.com - January 10 at 8:39 AMSanthera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - January 9 at 9:05 AMSanthera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meetingtechnews.tmcnet.com - November 29 at 8:31 PMSanthera Calls Extraordinary General Meeting to Seek Approval for Further Financingsfinance.yahoo.com - November 4 at 10:49 AMSanthera Announces Half-Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - October 31 at 2:16 AMEuropean Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - October 31 at 2:16 AMSanthera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - October 27 at 5:31 AMSanthera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congressfinance.yahoo.com - October 10 at 3:14 AMSanthera Pharmaceuticals Holding AG (SANN)uk.investing.com - October 6 at 4:11 AMSanthera Submits MAA For Vamorolone In Europe To Treat Duchenne Muscular Dystrophynasdaq.com - October 3 at 7:58 AMSanthera Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - October 3 at 1:55 AMSanthera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of Octoberfinance.yahoo.com - September 29 at 2:38 AMJAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - September 1 at 5:02 AMSanthera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophyfinance.yahoo.com - August 22 at 1:10 AMSanthera’s Shareholders Approve all Board Proposals at Today’s Annual General Meetingfinance.yahoo.com - June 30 at 6:33 PMSanthera Pharmaceuticals Holding AG: Santhera Updates on Ongoing NDA Submission for Vamorolonefinanznachrichten.de - June 29 at 3:49 AMSanthera Updates on Ongoing NDA Submission for Vamorolonefinance.yahoo.com - June 29 at 3:49 AMSanthera Pharmaceuticals Holding AG: Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Boardfinanznachrichten.de - June 28 at 10:49 PMSanthera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Boardfinance.yahoo.com - June 27 at 6:17 PMSanthera Reports 2021 Annual Resultsfinance.yahoo.com - June 10 at 2:56 AMSanthera Pharmaceuticals Holding AG: Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conferencefinanznachrichten.de - June 9 at 1:50 AMSanthera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conferenceapnews.com - June 9 at 1:50 AMSanthera Announces Corporate Calendar Updatefinance.yahoo.com - June 3 at 3:37 PM Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address SPHDF Media Mentions By Week SPHDF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPHDF News Sentiment▼0.000.52▲Average Medical News Sentiment SPHDF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPHDF Articles This Week▼00▲SPHDF Articles Average Week Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABCZF News AGTX News AGNPF News AKBLF News DRTSW News APGNW News ARNI News ASCLF News AVCTF News AWKNF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (OTCMKTS:SPHDF) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santhera Pharmaceuticals Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.